Lowenstein

THE RITZ-CARLTON, SOUTH BEACH CHAMPIONS LOCAL ARTISTS FOR MIAMI ART WEEK 2022 AND CONTINUES ART FOR GOOD INITIATIVE

Retrieved on: 
Mittwoch, November 9, 2022
Symposium (Xenophon), Bass, NASDAQ, The Ritz-Carlton Hotel Company, Israel ben Josef, SPG, Wine, Miami Sound Machine, Art Basel, Starwood, Collection, Lowenstein, Chevy Chase, Program, Music, Miami City Ballet, Russian Art Week, Art, Guantanamera, Culture, Good, Bal Harbour, Florida, History, Ownership, Morris Lapidus, Art Deco, Multimedia, Video game, Tourism, Nightclub, Hotel, L.L.C, Morris, Marriott International, Facebook

MIAMI, Nov. 9, 2022 /PRNewswire/ -- The Ritz-Carlton, South Beach - together with hotel ownership from the Ben Josef, Kanavos, and Lowenstein families - is extremely proud to continue its Art For Good program this Miami Art Week 2022 by celebrating 70 years of the landmark Morris Lapidus building as a cornerstone of South Beach. The hotel is a pillar of Miami's iconic history and now celebrates its commitment to the community with the help of brilliant local artists across various disciplines, including innovative design, dynamic music, and contemporary dance.

Key Points: 
  • MIAMI, Nov. 9, 2022 /PRNewswire/ -- The Ritz-Carlton, South Beach - together with hotel ownership from the Ben Josef, Kanavos, and Lowenstein families - is extremely proud to continue its Art For Good program this Miami Art Week 2022 by celebrating 70 years of the landmark Morris Lapidus building as a cornerstone of South Beach.
  • The Ritz-Carlton, South Beach - a Miami Beach Art Basel 2022 official hotel partner - is hosting this multi-sensory celebration to showcase to Art Week guests from across the globe, why Miami is home to Art Basel and other major fairs.
  • Spotlighting local talents, The Ritz-Carlton, South Beach highlights an expansive interpretation of art including the creative manifestations of architects, designers, musicians, dancers, and more.
  • To learn more about The Ritz-Carlton, South Beach's Art For Good program and additional Miami Art Week activities, please visit the hotel's website .

Retired New Jersey State Supreme Court Justice Barry T. Albin Joins Lowenstein as Partner in Litigation Department and Chair of the Appellate Practice Group

Retrieved on: 
Donnerstag, Juli 14, 2022
Technology, New Jersey Division of Alcoholic Beverage Control, Goldman, Private sector, Family, Criminal law, Cornell Law School, Rutgers University, Ethics, Justice, Supreme court, Insurance, Lawyer, White collar, Assistant, Appeal, Lawsuit, Civil and political rights, Court, Lowenstein, Supreme Court of New Jersey, Practice of law

ROSELAND, N.J., July 14, 2022 /PRNewswire/ -- Lowenstein Sandler is pleased to announce that former New Jersey Supreme Court Justice Barry T. Albin has joined the firm as partner in the firm's Litigation department and will chair the Appellate Practice Group.

Key Points: 
  • ROSELAND, N.J., July 14, 2022 /PRNewswire/ -- Lowenstein Sandler is pleased to announce that former New Jersey Supreme Court Justice Barry T. Albin has joined the firm as partner in the firm's Litigation department and will chair the Appellate Practice Group.
  • When Justice Albin retired in July 2022, after 20 years on the state's highest court, NJ.com called him "a consummate juristdedicated, social, diligent, practical."
  • As a Supreme Court Justice, Albin authored more than 400 opinions, including more than 230 majority opinions, more than 130 dissents, and dozens of concurrences.
  • Albin says: "My long career has intersected with many outstanding Lowenstein lawyers, some of whom have served as my clerks.

PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

Retrieved on: 
Dienstag, Februar 1, 2022
Disease, Holding, CEO, Disorder, Patient, CSE, Mortality, Amyotrophic lateral sclerosis, Consciousness, Food, Seizure, Status epilepticus, Ketamine, Lowenstein, ODD, Nerve, Pain disorder, Orphan Drug Act of 1983, Emergency, Orphan, Marketing, Orphan drug, OTCQB, Mental health, DeLorenzo, Incidence, GLOBE, Benzodiazepine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Quality of life, Lists of diseases, SE, Neurological disorder, Pharmaceutical industry

TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for ketamine to treat Status Epilepticus (SE), a rare neurological disorder requiring emergency treatment for a seizure.

Key Points: 
  • TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for ketamine to treat Status Epilepticus (SE), a rare neurological disorder requiring emergency treatment for a seizure.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
  • This status is referred to as orphan designation (or sometimes orphan status).
  • The FDA grants orphan status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

Retrieved on: 
Mittwoch, November 24, 2021
Patient, Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mental health, Disorder, Neurological disorder, Company, Lowenstein, Benzodiazepine, Lists of diseases, Seizure, Status epilepticus, Ketamine, ODD, SE, Disease, Nerve, CSE, Orphan, Consciousness, Research, GLOBE, Incidence, Marketing, Orphan drug, OTCQB, DeLorenzo, FDA, Amyotrophic lateral sclerosis, Mortality, Infection, Emergency, Orphan Drug Act of 1983, Food, Quality of life, Pharmaceutical industry

The Company has received FDA ODD for ketamine to treat amyotrophic lateral sclerosis (ALS) and complex regional pain syndrome (CRPS).

Key Points: 
  • The Company has received FDA ODD for ketamine to treat amyotrophic lateral sclerosis (ALS) and complex regional pain syndrome (CRPS).
  • The FDA orphan drug application for ketamine to treat status epilepticus builds on our belief in the potential of ketamine to improve quality of life and to save lives.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
  • The FDA grants orphan status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

VNUE to Acquire Livestreaming Company Stageit

Retrieved on: 
Donnerstag, Juli 29, 2021
Stageit, Lowenstein, Livestreaming, Multimedia, Digital media, Internet

NEW YORK, July 29, 2021 /PRNewswire/ -- In a strategic double-whammy, music technology company VNUE, Inc. (OTC: VNUE) today announced that the company is acquiring live streaming innovator StageIt in a deal that will add over nine million in revenue and access to thousands of performers and creators.

Key Points: 
  • NEW YORK, July 29, 2021 /PRNewswire/ -- In a strategic double-whammy, music technology company VNUE, Inc. (OTC: VNUE) today announced that the company is acquiring live streaming innovator StageIt in a deal that will add over nine million in revenue and access to thousands of performers and creators.
  • The companies expect to close within 60 days pending the completion of diligence and the required financial audit, and Stageit will become a wholly-owned subsidiary of VNUE.
  • StageIt, launched by musician Evan Lowenstein in 2010, is one of the earliest and most prominent live streaming companies.
  • Lowenstein has served as Executive Chairman of StageIt since music industry veteran Stephen White joined as CEO in 2020.

Anticipated Spike in Deal Activity in 2021 Makes Customized R&W Insurance Critical, Finds Lowenstein Sandler

Retrieved on: 
Donnerstag, November 12, 2020
Infectious diseases, Professional services, Health, Insurance, Finance, Money, Economy, Corporate finance, Mergers and acquisitions, Private equity, Lowenstein, Law firm

Encouraging news about COVID-19 vaccination trials and the impending resolution of the long election process bode well for deal activity in 2021, according to M&A and insurance recovery lawyers from Lowenstein Sandler.

Key Points: 
  • Encouraging news about COVID-19 vaccination trials and the impending resolution of the long election process bode well for deal activity in 2021, according to M&A and insurance recovery lawyers from Lowenstein Sandler.
  • The last decades deal activity spurred the growth of R&W insurancean alternative risk-transfer mechanism to indemnify buyers for breaches stemming from a sellers misrepresentations in acquisition agreements.
  • Lowensteins Mergers & Acquisitions group saw deal activity slow slightly in the early months of the pandemic, only to pick up dramatically in recent months.
  • Notably, the firms private equity deal activity continues to trend upward, so much so that Lowenstein Sandler has ranked among top law firms by number of deals in private equity for seven consecutive quarters in The Deal .

Lowenstein Sandler Represents Longtime Client Indorama Ventures in $2.1 Billion Acquisition

Retrieved on: 
Donnerstag, August 8, 2019
Consulting, Banking, Manufacturing, Professional services, Other Professional Services, Legal, Chemicals, Plastics, Finance, Surname, Rajasthani people, Humans, Indorama Ventures, Aloke Lohia, Names, Sandler, Lohia, Lowenstein, Speciality chemicals, Consulting, Banking, Manufacturing, Professional services, Other Professional Services, Legal, Chemicals, Plastics, Finance, Surname, Rajasthani people, Humans, Indorama Ventures, Aloke Lohia, Names, Sandler, Lohia, Lowenstein, Speciality chemicals

Lowenstein Sandler is representing its longtime client, Indorama Ventures Public Company Limited (BKK:IVL), Thailands leading global chemical company, in the high-profile $2.1 billion acquisition of the specialty chemicals portfolio of Huntsman Corporation USA (NYSE:HUN).

Key Points: 
  • Lowenstein Sandler is representing its longtime client, Indorama Ventures Public Company Limited (BKK:IVL), Thailands leading global chemical company, in the high-profile $2.1 billion acquisition of the specialty chemicals portfolio of Huntsman Corporation USA (NYSE:HUN).
  • With this transaction, involving the acquisition of five manufacturing sites, Lowenstein has now advised Indorama as lead counsel on the acquisition of a total of 16 facilities since 2003.
  • Aloke Lohia, Group CEO of Indorama Ventures, said, This acquisition is a momentous part of our journey towards our stated goal of being a global, diversified chemicals company with multiple and related earning streams.
  • Lowenstein Sandler is a national law firm with over 300 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C.

Olga Vodolazschi, Esq., LL.M., Promoted to Partner at International Tax Firm Lopez Levi Lowenstein Glinsky P.A.

Retrieved on: 
Montag, September 17, 2018
Lowenstein, International taxation

CORAL GABLES, Fla., Sept. 17, 2018 /PRNewswire/ --International Tax Firm Lopez Levi Lowenstein Glinsky, P.A.

Key Points: 
  • CORAL GABLES, Fla., Sept. 17, 2018 /PRNewswire/ --International Tax Firm Lopez Levi Lowenstein Glinsky, P.A.
  • Ms. Vodolazschi joined the firm in October of last year as Director of International Tax.
  • Olga focuses her practice in areas of international tax and compliance, immigration planning, real estate structuring, and estate planning.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/olga-vodolazschi-esq-llm-promote...
    SOURCE Lopez Levi Lowenstein Glinsky, P.A.